LPP anticorps (AA 1-109)

N° du produit ABIN2745541

Détail du produit anti-LPP anticorps

Antigène: LPP (Lipoma-preferred partner (LPP))

Épitope: AA 1-109

Reactivité: Humain, Rat, Porc

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LPP est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunocytochemistry (ICC)

Specificité: Recognizes human, rat and pig LPP.

Réactivité croisée: Humain, Porc, Rat (Rattus)

Purification: Antigen affinity purified.

Ingrédients: Contains Positive Control: Human skin fibroblast protein, supplied at 1mg/ml in SDS (Laemmli) sample buffer. Use 25μl (25μg) per lane for Western blotting.

Immunogène: Recombinant human lipoma preferred partner (LPP) (aa 1-109).

Information d'application

Indications d'application: Use 25 μL (25 μg) per lane for Western blotting.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 0.01 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Date de péremption: 12 months

Détails sur LPP

Antigène: LPP (Lipoma-preferred partner (LPP))

Autre désignation: Lipoma Preferred Partner (LPP Produits)

Synonymes: anticorps 9430020K16Rik, anticorps AA959454, anticorps AU024130, anticorps B130055L10Rik, anticorps C79715, anticorps D630048H16, anticorps LIM domain containing preferred translocation partner in lipoma, anticorps LPP, anticorps Lpp

Sujet: Lipoma preferred partner (LPP) is encoded by the preferred fusion partner gene of the high mobility group protein HMGI-C. LPP is frequently affected by chromosomal translocations in a major group of soft tissue lipomas, as well as in a parosteal lipoma and in pulmonary chondroid hamartomas. The resulting fusion proteins comprise three DNA binding domains of HMGI-C fused to two or three C-terminal LIM domains of LPP and a reciprocal product, respectively. Expression of a HMGI-C/LPP fusion protein causes malignant transformation of fibroblasts. Similar to its relatives zyxin and TRIP (thyroid receptor interacting protein 6) / ZRP-1 (zyxin-related protein 1), LPP consists of a N-terminal proline-rich domain followed by three C-terminal LIM domains (double zinc finger structures that are involved in protein-protein interactions). Like the cytoskeletal protein zyxin, LPP localizes to focal adhesions and cell-cell adherens junctions. LPP harbors a nuclear export signal and displays transcriptional activation capacity.

UniProt: Q93052